Sepracor Inc. to Become Sunovion Pharmaceuticals Inc.
	Sepracor Reports Preliminary Results from a Second Phase III Study for OMNARIS® HFA Nasal Aerosol in Seasonal Allergic Rhinitis
	FDA Provides Complete Response to Sepracor's New Drug Application For STEDESA™
	Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia